Publications

Bajraktari-Sylejmani G*, Kamaraj R*, Theile D, Pávek P, Weiss J. The “specific” P-glycoprotein inhibitor zosuquidar (LY335979) also weakly inhibits human organic cation transporters. Naunyn-Schmiedebergs Arch Pharmacol 2025;398:7147-53. *equal contribution

Bajraktari-Sylejmani G, Piribauer M, Groessl S, Bernhard P, Dyckhoff G, Warta R, Herold-Mende C, Theile D*, Weiss J*. Kynurenine enhances aryl hydrocarbon receptor signaling and expression levels of multidrug resistance genes in head and neck squamous cell carcinoma cell lines but does not change the potency of antineoplastic drugs. Toxicol Appl Pharmacol 2025;502:117443. * equal contribution

Benning L, Reineke M, Rodrigues CE, Kälble F, Speer C, Sommerer C, Mahler CF, Schmitt FCF, Mieth M, Zeier M, Michalski C, Mehrabi A, Hartmann O, Zorn M, Anker SC, Czock D, Weigand MA, Endre Z, Morath C, Nusshag C. Proenkephalin A 119-159 in kidney transplantation: A novel biomarker for superior tracking of graft function trajectories. Transplant International 2025;38:14366.

Beyer F, Kleine L, Zülke A, Luppa M, Mildner T, Gensichen J, Frese T, Czock D, Wiese B, König HH, Kaduszkiewicz H, Hoffmann W, Thyrian JR, Villringer A, Riedel-Heller S, Witte AV. Exploring the effect of multi-modal intervention against cognitive decline on atrophy and small vessel disease imaging markers in the AgeWell.de imaging study. Neuroimage Clin 2025;46:103796.

Brockmüller C, Meid AD, Senges J, Hochadel M, Haefeli WE, Stoll F. Phenotypes of patients with direct oral anticoagulant (DOAC) underdosing in atrial fibrillation – results from the ARENA registry. Clin Drug Invest 2025; 45:29-43.

Claus M, Luppa M, Zülke A, Blotenberg I, Cardona MI, Döhring J, Escales C, Kosilek RP, Oey A, Zöllinger I, Brettschneider C, Czock D, Frese T, Gensichen J, Hoffmann W, Kaduszkiewicz H, König HH, Wiese B, Thyrian JR, Riedel-Heller SG. Potential for reducing dementia risk: association of the CAIDE score with additional lifestyle components from the LIBRA score in a population at high risk of dementia. Aging Ment Health 205;29:400-7.

Derobertmasure A, Toh LS, Wotring VE, Williams PM, Morbidelli L, Stingl JC, Vinken M, Ramadan R, Chhun S, Boutouyrie P. Pharmacological countermeasures for long-duration space missions: addressing cardiovascular challenges and advancing space-adapted healthcare. Eur J Pharm Sci 2025;209:107063. 

Kehr D, Ritterhoff J, Glaser M, Jarosch L, Salazar R, Spaich K, Varadi K, Birkenstock J, Egger M, Gao E, Koch W, Sauter M, Freichel M, Katus H, Frey N, Jungmann A, Busch C, Mather P, Ruhparwar A, Busch M, Völkers M, Wade R, Most P. S100A1ct: a synthetic peptide derived from S100A1 protein improves cardiac performance and survival in pre-clinical heart failure models. Circulation 2025;151:548-565.

Klein AA, Petermann J, Brosse F, Piller S, Hanf M, Dinh TS, Schulz-Rothe S, Mergenthal K, Schäfer L, Seidling HM, Klasing S, Bahareh Y, Timmesfeld N, van den Akker M, Voigt K. Health information management of older, multimorbid patients in German primary care: feasibility and first results of the outcome measures of a cluster-randomised controlled pilot trial – HYPERION-TransCare. BMC Primary Care 2025;26:98.

Korompoki E, Heuschmann P, Harvey KH, Fiessler C, Malzahn U, Hügen K, Ullmann S, Todd GP, Schuhmann C, Montaner J, Sibon I, Debette S, Enzinger C, Ropele S, Rücker V, Haas K, Harvey E, Wolfe C, Wang Y, Nielsen PB, Caso V, Lip GYH, Lane DA, Halse O, Ringleb P, Haefeli WE, Foerster KI, Wurmbach VS, Veltkamp R. Prevention of stroke in intracerebral haemorrhage survivors with atrial fibrillation: Rationale and design for PRESTIGE-AF trial. Thromb Haemost 2025;125:395-403.

Krohmer E, Haefeli WE. Comment on: Increased theophylline plasma concentrations in a patient with Covid-19. Ann Pharmacother 2025;59:587. 

Krohmer E, Rohr BS, Stoll F, Gümüs KS, Bergamino M, Mikus G, Sauter M, Burhenne J, Weiss J, Meid AD, Czock D, Blank A, Haefeli WE. Influence of a short course of ritonavir as used as booster in antiviral therapies against SARS-CoV-2 on the exposure of atorvastatin and rosuvastatin. Cardiovasc Drugs Ther 2025;39:325-35.

Lamadrid A, Leiva-Escobar I, Jeffery C, Anguyo RJ, Lako R, Valadez JJ. Prevalence, locations and predictors of attitudes accepting both intimate partner violence and additional forms of violence against women and girls in South Sudan: a geospatial analysis. PLOS Glob Public Health 2025;5:e0004144.

Lampertico P, Bogomolov PO, Chulanov V, Stepanova T, Morozov V, Allweiss L, Dandri M, Burhenne J, Blank A, Ciesek S, Elsner C, Dittmer U, An Q, Manuilov D, Da BL, Flaherty JF, Urban S, Wedemeyer H. A phase 2 randomized study of bulevirtide given as monotherapy or in combination with pegylated interferon α 2a as treatment for chronic hepatitis delta. Liver Int 2025;45:e70008.

Leiva-Escobar I, Cortes CP, Lamadrid A. Employment status and HIV viral load in Chilean adult population: A propensity score analysis. AIDS Behav 2025;29:1256-65.

Lenard A, Hermann SA, Stoll F, Burhenne J, Foerster KI, Czock D, Mikus G, Meid AD, Haefeli WE, Blank A. Effect of the frequently used antiepileptic drugs carbamazepine, gabapentin, and pregabalin on the pharmacokinetics of edoxaban and other oral factor Xa inhibitors in healthy volunteers. Front Pharmacol 2025;16:1542063.

Poß-Doering R, Brinkmöller S, Balzer A, Wurmbach VS, Paul C, Stolz R, Zugaj MR, Tesarz J, Wensing M, Straßner C. Resource-oriented case management to implement recommendations for patients with chronic pain and frequent use of analgesics in general practices (Project RELIEF): Protocol for a single-arm exploratory feasibility study. JMIR Res Protoc 2025;14:e66335.

Sarömba JA, Müller JP, Tupiec J, Roeth A, Kurt B, Kahles F, Laurentius T, Bollheimer C, Stingl JC, Just KS. Solanidine-derived CYP2D6 phenotyping elucidates phenoconversion in multimedicated geriatric patients. Br J Clin Pharmacol 2025;91:1842-52.

Scherkl C, Dierkes T, Metzner M, Czock D, Seidling HM, Haefeli WE, Meid AD. Towards a prescribing monitoring system for medication safety evaluation within electronic health records: A scoping review. BMC Med Inform Decis Mak 2025;25:244.

Stephan C, Kloor D, Wurmbach VS, Mahler C. Instruments for measuring healthcare professionals' medication safety competence: A scoping review. J Multidiscip Healthc 2025;18:1745-58.

Stingl J, Scholl C, Steffens M, Koczera P, Muche R, Rohlmann F, Ettrich T, Seufferlein T. Genomewide association analysis on green tea chemoprevention of colorectal adenoma: the importance of SLCO1A2 variants. Pharmacogenomics 2025;26:157-64.

Stingl JC, Viviani R. Pharmacogenetic guided drug therapy - how to deal with phenoconversion in polypharmacy. Expert Opin Drug Metab Toxicol 2025;21:399-407.

Stoll F, Amato S, Burhenne J, Blank A. In vivo effect of bempedoic acid on microdosed CYP probe drugs. Front Pharmacol 2025;16:1544956.

Stoll F, Amato S, Sauter M, Burhenne J, Weiss J, Haefeli WE, Blank A. Effect of staggered vs. simultaneous co-administration of bempedoic acid on pharmacokinetics of pravastatin: randomized, cross-over clinical trial in healthy volunteers. Pharmaceutics 2025;17:60.

Sundheimer J*, Benzel J*, Longuespée R, Burhenne J, Pfister S, Maaß K, Sauter M*, Pajtler K*. Experimental insights and recommendations for successfully performing cerebral microdialysis with hydrophobic drug candidates. Clin Transl Sci 2025;18:e70226. * equal contribution

Toklucu I, Eswaran VSB, Bott RA, Kesdoğan AB, Gaebler AJ, Stingl J, Hausmann R, Körner J, Lampert A. α-Adrenoreceptor blocker phentolamine inhibits voltage-gated sodium channels via the local anaesthetic binding site. Br J Pharmacol 2025;182:1879-96.

Veltkamp R, Korompoki E, Harvey KH, Harvey ER, Fießler C, Malzahn U, Rücker V, Montaner J, Caso V, Sibon I, Ringleb P, Halse O, Hügen K, Ullmann S, Schuhmann C, Todd GB, Haas K, Palà E, Debette S, Lachaize M, D'Aoust T, Enzinger C, Ropele S, Fandler-Höfler S, Haidegger M, Wang Y, Wafa HA, Cancelloni V, Mosconi MG, Lip GYH, Lane DA, Haefeli WE, Foerster KI, Wurmbach VS, Nielsen PB, Hajjar K, Müller P, Poli S, Purrucker J, Laible M, D'Anna L, Silva Y, de Torres Chacon R, Martínez-Sánchez P, Boulanger M, Norrving B, Paré G, Wachter R, Ntaios G, Wolfe CDA, Heuschmann PU, on behalf of the PRESTIGE-AF Consortium. Direct oral anticoagulants versus no anticoagulation for the prevention of stroke in survivors of intracerebral haemorrhage with atrial fibrillation (PRESTIGE-AF): a multicentre, open-label, randomised, phase 3 trial. Lancet 2025;405:927-36.

Vogt CJ, Wiegand A, Trajkov K, Metzner M, Wurmbach VS, Braem A, Seidling HM. Attitudes and expectations toward medication review among community pharmacy customers in Germany: a cross-sectional study. J Pharm Policy Pract 2025;18:2490572.

Weber S, Lampert A, Stingl JC, Peuckmann-Post V, Hiddemann S, Elsner F, Neuner I, Rolke R. Basiswissen zur medikamentösen Schmerztherapie in der Palliativsituation [Basic knowledge of drug pain therapy in the palliative situation]. Dtsch Med Wochenschr 2025;150:817-25. 

Wintermark P, Lapointe A, Altit G, Steinhorn R, Rampakakis E, Meid AD, Burhenne J, Bajraktari-Sylejmani G, Khairy M, Adamo M-T, Gilbert G, Toffoli D, Zavalkoff S, Luu TM, Hailu E, Haefeli WE. Testing higher doses of sildenafil to repair brain injury secondary to birth asphyxia: An open-label dose-finding phase 1b study (SANE-02). J Pediatrics 2025;285:114701.

Yamoune S, Koch H, Delev D, Weber Y, Stingl JC. Evaluation of stabilizing additives to protect activities of cytochrome P450 enzymes for in vitro drug testing and pharmacogenetic studies: Focus on CYP2D6. Biochim Biophys Acta Gen Subj 2025;1869:130770.

Publikationen im Druck 2025

Bay C, Uhl P, Meid AD, Burhenne J, Haefeli WE, Sauter M. Quantification of arginine-rich cyclic cell-penetrating peptide-lipid conjugates using a surrogate peptide extracted by phospholipase D digestion and trifluoroacetic acid-based UPLC-MS/MS analysis. Analytical Chemistry, in press.

Guchelaar HJ, van der Wouden CH, Manson LEN, Abdullah-Koolmees H, Blagec K, Blagus T, Böhringer S, Cecchin E, Cheung KC, Deneer VHM, Jonsson S, Joefield-Roka C, Just KS, Karlsson MO, Konta L, Koopmann R, Kriek M, Lehr T, Mitropoulou C, Rollinson V, Roncato R, Samwald M, Schaeffeler E, Skokou M, Schwab M, Steinberger D, Stingl JC, Tremmel R, Turner RM, van Rhenen MH, Dávila-Fajardo CL, Dolžan V, Patrinos GP, Pirmohamed M, Sunder-Plassmann G, Toffoli G, Swen JJ; Ubiquitous Pharmacogenomics Consortium. Pharmacogenetic implementation studies-lessons learned from the PREPARE study. Clin Pharmacol Ther, in press.

Harvey KH, Korompoki E, Harvey ER, Fießler C, Malzahn U, Hügen K, Ullmann S, Schuhmann C, Putz Todd G, Montaner J,Penalba A, Guaman-Pilco D, Sibon I, Debette S, D'Aoust T, Lachaize M, Enzinger C, Ropele S, Fandler-Höfler S, Ruecker V, Haas K, Nielsen PB, Wolfe C, Wang Y, Wafa H, Caso V, Mosconi MG, Lip GYH, Lane DA, Haefeli WE, Foerster KI, Wurmbach VS, Ringleb P, Heuschmann PU, Veltkamp R. Personalized medicine, public health and patient-centred aspects in the prevention of stroke in intracerebral haemorrhage survivors with atrial fibrillation (PRESTIGE-AF) Project. Thromb Haemost, in press.

Leiva-Escobar I, Scherkl C, Haefeli WE, Meid AD. Transporting trial results to synthetic real-world populations in order to estimate real-world effectiveness of newly marketed medicines. BMJ Open, in press.

Lepenies LK, Seidling HM, Pabst A, Luppa M, Döhring J, Williamson M, Frese T, Gensichen J, Hoffmann W, Kaduszkiewicz H, König HH, Thyrian JR, Wiese B, Steffi G. Riedel-Heller SG, Czock D. Deprescribing drugs with anticholinergic effects in older patients with increased risk of dementia in the multicomponent intervention study AgeWell.de. Br J Clin Pharmacol, in press.

Morath B, Foerster KI, Chiriac U, Zaradzki M, Hoppe-Tichy T, Schrey D, Burhenne J, Czock D, Karck M, Haefeli WE, Wicha SG. Effect of amiodarone on apixaban exposure in patients after cardiac surgery – a population pharmacokinetic study. Clin Pharmacokinet, in press.

O'Neill S, Bidulka P, Lugo-Palacios DG, Carroll O, Leiva-Escobar I, Silverwood R, Briggs A, Adler AI, Khunti K, Grieve R. Comparative effectiveness of alternative second-line oral glucose-lowering therapies for type 2 diabetes: a precision medicine approach applied to routine data. Diabetologia, in press.

Weber F, Scharf C, Aulin LBS, Weinelt F, Paal M, Mikus G, Vogeser M, Habler K, Huisinga W, Zoller M, Michelet R, Kloft C, Liebchen U. Model-informed identification of optimised dosing strategies for meropenem in critically ill patients receiving SLEDD: an observational study. Infection, in press.

Wild B*, Wurmbach VS*, Boehlen FH, Kusch M, Paul C, Friederich HC, Hartmann M, Slaets J, Seidling HM. What do we need to know to enhance treatment for multimorbid older patients?-Results from the PACT study. Aging Ment Health, in press. *equal contribution

Buchbeiträge

Czock D, Ebinger K, Sommerer C. Nephrotoxizität von Arzneimitteln. In: Mertens PR, Editor. Rationelle Diagnostik und Therapie in der Inneren Medizin – Nephrologie. 1. Auflage München: Elsevier GmbH; 2025. S. 165-70.

Alexander GC, Budnitz D, Hughes C, Maas R, Mair A, McDonald EG, Meid AD, Payne R, Seidling HM, Shakir S, Suissa S, Tannenbaum C, Schneeweiss S, Dreischulte T. Proceedings of the international ambulatory drug safety symposium: Munich, Germany, June 2023. Drug Saf 2024; 47:103-11.

Arnet I, Sahm LJ, Gregório J, Tuula A, Krüger M, Wurmbach VS, Hoti K, Schulz M, Eickhoff C. Development and validation of the 15-STARS - A novel self-report pharmacy-based questionnaire to screen for medication non-adherence. Res Social Adm Pharm 2024;20:308-20.

Bajraktari-Sylejmani G, Oster JS, Burhenne B, Haefeli WE, Sauter M*, Weiss J*. In vitro evaluation of the reductive carbonyl idarubicin metabolism to evaluate inhibitors of the formation of cardiotoxic idarubicinol via carbonyl and aldo-keto reductases. Arch Toxicol 2024;98:807-20. * joint last authorship

Bajraktari-Sylejmani G, Bay, C, Gebauer L, Burhenne J, Weiss J*, Sauter M*. A highly sensitive UPLC-MS/MS method for the quantification of the organic cation transporters’ mediated metformin uptake and its inhibition in cells. Molecules 2024;29:5162. *joint last authorship

Bittmann JA, Scherkl C, Meid AD, Haefeli WE, Seidling HM. Event analysis for automated estimation of absent and persistent medication alerts: novel methodology. JMIR Med Inform 2024;12:e54428.

Buchholz M, Zöllinger I, Thyrian JR, Luppa M, Zülke A, Döhring J, Lunden L, Sanftenberg L, Brettschneider C, Czock D, Frese T, Gensichen J, Hoffmann W, Kaduszkiewicz H, König HH, Wiese B, Riedel-Heller SG, Blotenberg I. Factors associated with lower social activity in German older adults at increased risk of dementia: a cross-sectional analysis. J Alzheimers Dis 2024;98:1443-55.

Dinh TS, Hanf M, Klein AA, Brueckle MS, Rietschel L, Petermann J, Brosse F, Schulz-Rothe S, Klasing S, Muth C, Seidling H, Engler J, Mergenthal K, Voigt K, van den Akker M. Informational continuity of medication management in transitions of care: Qualitative interviews with stakeholders from the HYPERION-TransCare study. PLoS One 2024;19:e0300047.

Döhring J, Williamson M, Brettschneider C, Fankhänel T, Luppa M, Pabst A, Weißenborn M, Zöllinger I, Czock D, Frese T, Gensichen J, Hoffmann W, König HH, Thyrian JR, Wiese B, Riedel-Heller S, Kaduszkiewicz H. Quality of life in a high-risk group of elderly primary care patients: characteristics and potential for improvement. Qual Life Res 2024;33:1841-51.

Falconnier-Williams OC, Taeschner W, Hille A, Falconnier AD, Haefeli WE. Untapped options to reduce waste from blister packaging for tablets and capsules. Eur J Clin Pharmacol 2024;80:151-61.

Gola AM, Bucci-Muñoz M, Rigalli JP, Ceballos MP, Ruiz ML. Role of the RNA binding protein IGF2BP1 in cancer multidrug resistance. Role of the RNA binding protein IGF2BP1 in cancer multidrug resistance. Biochem Pharmacol 2024,230:116555.

Gümüs KS*, Teegelbekkers A*, Sauter M, Meid AD, Burhenne J, Weiss J, Blank A, Haefeli WE, Czock D. Effect of tacrolimus formulation (prolonged-release vs. immediate-release) on its susceptibility to drug-drug interactions with St. John’s Wort. Clin Pharmacol Drug Dev 2024;13:297-306. * joint first authorship

Hilgarth H, Gradl G, Metzger NM, Dörje F, Schulz M, Wolf C, Seidling HM. Einsatz von Entlassrezepten - Ein Überblick aus Deutschland für die Jahre 2018–2021. Dtsch Arztebl Int 2024; 121: 539-40.

Hohmann N, Friedrichs AS, Burhenne J, Blank A, Mikus G, Haefeli WE. Dose-dependent induction of CYP3A activity by St. John's wort alone and in combination with rifampin. Clin Transl Sci 2024;17:e70007.

Hose D, Ray S, Rößler S, Thormann U, Schnettler R, de Veirman K, El Khassawna T, Heiss C, Hild A, Zahner D, Alagboso F, Henss A, Beck S, Emde-Rajaratnam M, Burhenne J, Bamberger J, Menu E, de Bruyne E, Gelinsky M, Kampschulte M, Rohnke M, Wenisch S, Vanderkerken K, Hanke T, Seckinger A, Alt V. Bortezomib-releasing silica-collagen xerogels for local treatment of osteolytic bone- and minimal residual disease in multiple myeloma. J Hematol Oncol 2024;17:128

Kappe J, Wittmann F, Luppa M, Cardona MI, Weise S, Fuchs S, Kosilek RP, Sanftenberg L, Brettschneider C, Döhring J, Escales C, Czock D, Wiese B, Thyrian JR, Hoffmann W, Frese T, Gensichen J, König HH, Kaduszkiewicz H, Riedel-Heller SG. General practitioners' perspectives on lifestyle interventions for cognitive preservation in dementia prevention. BMC Prim Care 2024;25:301.

Klasing S, Dörje F, Hilgarth H, Metzger N, Richling I, Seidling HM. Continuity of medication information transfer and continuous medication supply during hospital-to-home transitions - nationwide surveys in hospital and community pharmacies after implementing new legal requirements in Germany. BMC Health Serv Res 2024;24:993.

Klasing S, Jungreithmayr V, Morath B, Scherkl C, Meid AD, Haefeli WE, Seidling HM. [Quality of medication documentation in patients’ discharge summaries after implementing new legal requirements]. Z Evid Fortbild Qual Gesundhwes 2024;188:1-13.

Klein AA, Petermann J, Brosse F, Piller S, Kramer M, Hanf M, Dinh TS, Schulz-Rothe S, Engler J, Mergenthal K, Seidling HM, Klasing S, Timmesfeld N, van den Akker M, Voigt K. Implementation and evaluation of a complex intervention to improve information availability at the interface between inpatient and outpatient care in older patients with multimorbidity and polypharmacy (HYPERION-TransCare) - study protocol for a pilot and feasibility cluster-randomized controlled trial in general practice in Germany. Pilot Feasibility Stud 2023;9:146.

Kratzmann M, Blank A, Gümüs K, Eisenmenger A, Müller M. Papillomavirus Impfstoff PANHPVAX: Herausfordernde Schritte von der Idee zur Erstanwendungsstudie. Fachzeitschrift für pharmazeutische Medizin und Qualitätsmanagement 2004:26;4-11.

Lenard A, Hermann SA, Stoll F, Burhenne J, Foerster KI, Mikus G, Meid AD, Haefeli WE, Blank A. Effect of Clarithromycin, a strong CYP3A and P-glycoprotein inhibitor, on the pharmacokinetics of Edoxaban in healthy volunteers and the evaluation of the drug interaction with other oral factor Xa inhibitors by a microdose cocktail approach. Cardiovasc Drugs Ther 2024;38:747-56.

Loeffler M, Maas R, Neumann D, Scherag A. INTERPOLAR-prospective, interventional studies as part of the Medical Informatics Initiative to improve medication therapy safety in healthcare]. Bundesgesundheitsblatt-Gesund 2024;67:676-684

Longuespée R, Kunz J, Fresnais M, Foerster KI, Burhenne J, Thomas M, Kazdal D, Stenzinger A, Christopoulos P, Haefeli WE. Therapeutic drug monitoring of osimertinib in non-small cell lung cancer and short bowel syndrome: a case report. Br J Clin Pharmacol 2024;90:344-9.

Mc Laughlin AM, Helland T, Klima F, Koolen SLW , van Schaik R, Mathijssen RHJ, Neven P, Swen JJ, Guchelaar H-J, Dalenc F, White-Koning M, Michelet R, Mikus G, Schroth W, Mürdter T, Brauch H, Schwab M, Mellgren G, Thomas F, Kloft C, Hertz DL. Nonlinear mixed-effects model of Z-endoxifen concentrations in tamoxifen treated patients from the CEPAM cohort. Clin Pharmacol Ther 2024;116: 690-702.

Meid AD, Scherkl C, Metzner M, Czock D, Seidling HM. Real-world application of a quantitative systems pharmacology (QSP) model to predict potassium concentrations from electronic health records: A pilot case towards prescribing monitoring of spironolactone. Pharmaceuticals (Basel) 2024;17:1041

Mikus G. ChatGPT does make up scientific references, should it be currently renamed CheatGPT? Eur J Clin Pharmacol 2024; 80: 1995-6.

Nilles J, Theile D, Weiss J, Haefeli WE, Ruez S. Lack of CYP3A4 protein induction despite mRNA induction in primary hepatocytes exposed to rifabutin as a possible explanation for its low interaction risk in vivo. Arch Toxicol 2024;98:2541-56.

Nilles J, Weiss J, Masin M, Tuffs C, Strowitzki MJ, Haefeli WE, Ruez S, Theile D. The differences in drug disposition gene induction by rifampicin and rifabutin are unlikely due to different effects on important pregnane X receptor (NR1I2) splice variants. Naunyn Schmiedebergs Arch Pharmacol 2024;397:2485-96.

Paasche A, Wiedmann F, Kraft M, Seibertz F, Herlt V, Blochberger PL, Jávorszky N, Beck M, Weirauch L, Seeger T, Blank A, Haefeli WE, Arif R, Meyer AL, Warnecke G, Karck M, Voigt N, Frey N, Schmidt C. Acute antiarrhythmic effects of SGLT2 inhibitors-dapagliflozin lowers the excitability of atrial cardiomyocytes. Basic Res Cardiol 2024;119:93-112.

Phondeth L*, Kamaraj R*, Nilles J, Weiss J, Haefeli WE, Pávek P, Theile D. Rifabutin but not rifampicin can partly out-balance P-glycoprotein induction by concurrent P-glycoprotein inhibition through high affinity binding to the inhibitory site. Arch Toxicol 2024;98:223-31. * equal contribution

Poß-Doering R, Keller S, Zugaj M, Seidling H, Paul C, Stolz R, Kaufmann-Kolle P, Straßner C. Hausärztliche Versorgung von Patient:innen mit chronischen nicht-tumorbedingten Schmerzen: ein Rapid Review im Rahmen des RELIEF-Projekts. Z Evid Fortbild Qual Gesundheitswesen (ZEFQ) 2024;185:1-9.

Rigalli JP, Gagliardi A, Diester K, Bajraktari-Sylejmani G, Blank A, Burhenne J, Lenard A, Werntz L, Huppertz A, Münch L, Wendt JM, Sauter M, Haefeli WE, Weiss J. Extracellular vesicles as surrogates for the regulation of the drug transporters ABCC2 (MRP2) and ABCG2 (BCRP). Int J Mol Sci 2024;25:4118.

Rohr BS, Krohmer E, Foerster KI, Burhenne J, Schulz M, Blank A, Mikus G, Haefeli WE. Time course of the interaction between oral short-term ritonavir therapy with three factor Xa inhibitors and the activity of CYP2D6, CYP2C19, and CYP3A4 in healthy volunteers. Clin Pharmacokinet 2024;63:469-81.

Rose F*, Köberle B*, Honnen S, Bay C, Burhenne J, Weiss J, Haefeli WE, Theile D. RNA is a pro-apoptotic target of cisplatin in cancer cell lines and C. elegans. Biomed Pharmacother 2024;173:116450. * joint first authorship

Saleh A, Schulz J, Schlender JF, Aulin LBS, Konrad AP, Kluwe F, Mikus G, Huisinga W, Kloft C, Michelet R. Understanding voriconazole metabolism: A middle-out physiologically-based pharmacokinetic modelling framework integrating in vitro and clinical insights. Clin Pharmacokinet 2024;63:1609-30.

Schäfer L, Paulitsch M, Hanf M, Dinh TS, Klein A-A, Klasing S, Seidling H, Voigt K, van den Akker M. Polypharmacy in older patients with multimorbidity: the agreement between patient and general practitioner-reported drugs observed in a pilot cRCT. Int J Environ Res Public Health 2024;21:1389.

Scherkl C, Meid AD, Cuntz SE, Classen L, Weiss J, Czock D, Haefeli WE. Coadministration of fluconazole to boost subtherapeutic sirolimus concentrations: A case report. Pharmacol Res Perspect 2024;12:e1198.

Stoll F, Blank A, Mikus G, Czock D, Weiss J, Meyer-Tönnies MJ, Gümüs KS, Tzvetkov M, Burhenne J, Haefeli WE. Evaluation of hydroxychloroquine as a perpetrator on cytochrome P450 (CYP) 3A and CYP2D6 activity with microdosed probe drugs in healthy volunteers. Eur J Drug Metab Pharmacokinet 2024;49:101-9.

Terstegen T, Niestroj C, Stangl J, Scherkl C, Morath B, Haefeli WE, Seidling HM. Approaches to medication history taking in different hospital settings: A scoping review. Am J Health Syst Pharm 2024;81:e419-30.

Terstegen T, Kirchner M, Haefeli WE, Seidling HM. Proposal for a new study design and endpoint in research on medication history taking. J Pharm Policy Pract 2024;17:2396967

Theile D, Czock D. Perfusate flow rate: an overlooked factor in hyperthermic intraperitoneal chemotherapy (HIPEC)? Ann Surg Oncol 2024;31:8614-8615

Vogt CJ, Moecker R, Jacke CO, Haefeli WE, Seidling HM. Exploring the heterogeneity in community pharmacist-led medication review studies - A systematic review. Res Social Adm Pharm 2024;20:679-88.

Wedemeyer H, Aleman S, Brunetto M, Blank A, Andreone P, Bogomolov P, Chulanov V, Mamonova N, Geyvandova N, Morozov V, Sagalova O, Stepanova T, Berger A, Ciesek S, Manuilov D, Mercier RC, Da BL, Chee GM, Li M, Flaherty JF, Lau AH, Osinusi A, Schulze Zur Wiesch J, Cornberg M, Zeuzem S, Lampertico P. Bulevirtide monotherapy in patients with chronic HDV: Efficacy and safety results through week 96 from a phase 3 randomized trial. J Hepatol 2024;81:621-629

Wehran T, Eidam A, Czock D, Kopitz J, Plaschke K, Mattern M, Haefeli WE, Bauer JM, Seidling HM. Development and pilot testing of an algorithm-based approach to anticholinergic deprescribing in older patients. Drugs and Aging 2024;41:153-64.

Wintermark P, Lapointe A, Steinhorn R, Rampakakis E, Burhenne J, Meid AD, Bajraktari-Sylejmani G, Khairy M, Altit G, Adamo MT, Poccia A, Gilbert G, Saint-Martin C, Toffoli D, Vachon J, Hailu E, Colin P, Haefeli WE. Feasibility and safety of sildenafil to repair brain injury secondary to birth asphyxia (SANE-01): A randomized, double-blind, placebo-controlled phase Ib clinical trial. J Pediatr 2024;266:113879.

Wittmann FG, Pabst A, Zülke A, Luppa M, Blotenberg I, Cardona MI, Bauer A, Fuchs S, Zöllinger I, Sanftenberg L, Brettschneider C, Döhring J, Lunden L, Czock D, Wiese B, Thyrian JR, Hoffmann W, Frese T, Gensichen J, König HH, Kaduszkiewicz H, Riedel-Heller SG. Who benefited the most? Effectiveness of a lifestyle intervention against cognitive decline in older women and men - secondary analysis of the AgeWell.de-trial. J Prev Alzheimers Dis 2024;11:348-55.

Zülke AE, Pabst A, Luppa M, Roehr S, Seidling H, Oey A, Cardona MI, Blotenberg I, Bauer A, Weise S, Zöllinger I, Sanftenberg L, Brettschneider C, Döhring J, Lunden L, Czock D, Haefeli WE, Wiese B, Hoffmann W, Frese T, Gensichen J, König HH, Kaduszkiewicz H, Thyrian JR, Riedel-Heller SG. A multidomain intervention against cognitive decline in an at-risk-population in Germany – Results from the cluster-randomized AgeWell.de-trial. Alzheimers Dement 2024;20:615-28.

Zülke AE, Pabst A, Luppa M, Oey A, Weise S, Fankhänel T, Kosilek RP, Schillok H, Brettschneider C, Czock D, Wiese B, Thyrian JR, Hoffmann W, Frese T, Gensichen J, König HH, Kaduszkiewicz H, Riedel-Heller SG. Effects of a multidomain intervention against cognitive decline on dementia risk profiles - Results from the AgeWell.de trial. Alzheimers Dement 2024;5684-94.

Zülke AE, Blotenberg I, Luppa M, Löbner M, Döhring J, Williamson M, Kosilek RP, Michel I, Oey A, Brettschneider C; Gensichen J, Czock D, Wiese B, König HH, Frese T, Kaduszkiewicz H, Hoffmann W, Thyrian R, Riedel-Heller SG. Dietary changes following a lifestyle-based intervention for dementia risk reduction – Results from the AgeWell.de study. Eur J Nutr 2024;64:58

Buchbeiträge/Book contributions:

Haefeli WE. Software-basierte Assistenz in der Medikamentenverordnung. In Bauer JM, Becker C, Denkinger M, Wirth R (eds.). Geriatrie. Das gesamte Spektrum der Altersmedizin für Klinik und Praxis. Stuttgart: Kohlhammer; 2024. S. 75-9.

Czock D. Pharmakotherapie in der Niereninsuffizienz. In: Schwenger V (Hrsg.). Klinikleitfaden Nephrologie. 2. Auflage. München: Elsevier; 2024. 661-72.

Seidling HM, Haefeli WE. Aufgaben des Medikamentenmanagements. In: Euteneier A (Hrsg). Handbuch Klinisches Risikomanagement. 2. Auflage. Heidelberg: Springer; 2024. S. 215-22.

Seidling HM, Haefeli WE. Optimierung des Medikamentenmanagements. In: Euteneier A (Hrsg). Handbuch Klinisches Risikomanagement. 2. Auflage. Heidelberg: Springer; 2024. S. 595-600.

Bay C, Bajraktari-Sylejmani G, Haefeli WE, Burhenne J, Weiss J, Sauter M. Correction: Bay et al. Functional characterization of the solute carrier LAT-1 (SLC7A5/SLC3A2) in human brain capillary endothelial cells with rapid UPLC-MS/MS quantification of intracellular isotopically labelled L-leucine. Int.J.Mol.Sci.2022;23:3637. Int J Mol Sci 2023;24:5029.

Boettcher M, Duengen H-D, Corcea V, Donath F, Fuhr R, Gal P, Mikus G, Trenk D, Werner N, Pires PV, Maschke C, Aliprantis AO, Besche N, Becker C. Vericiguat: A randomized, phase Ib, placebo-controlled, double-blind, QTc interval study in patients with stable chronic coronary syndromes. Am J Cardiovasc Drugs 2023;23:145-55.

Carotti V, van Megen WH, Rigalli JP, Barros ER, Sommers V, Rutten L, Sommerdijk N, Peters DJM, van Asbeck-van der Wijst J, Hoenderop JGJ. Extracellular vesicles contribute to early cyst development in autosomal dominant polycystic kidney disease by cell-to-cell communication. FASEB J 2023;37:e23006.

Dinh TS*, Meid AD*, Rudolf H, Brueckle M-S, González-González AI, Bencheva V, Gogolin M, Snell KIE, Elders PJM, Thuermann PA, Donner-Banzhoff N, Blom JW, van den Akker M, Gerlach FM, Harder S, Thiem U, Glasziou PP, Haefeli WE, Muth C. Anticholinergic burden measures, symptoms, and fall-associated risk in older adults with polypharmacy: development and validation of a prognostic model. PLoS One 2023;18:e0280907.

Djaelani YA, Giese T, Sommerer C, Czock D. Pharmacodynamic monitoring of ciclosporin and tacrolimus: Insights from nuclear factor of activated T-cell-regulated gene expression in healthy volunteers. Ther Drug Monit 2023;45:87-94.

Eidam A, Marji J, Benzinger P, Foerster KI, Burhenne J, Czock D, Stoll F, Blank A, Mikus G, Haefeli WE, Bauer JM. Frailty as a marker for the plasma concentrations of direct oral anticoagulants in older patients: results of an exploratory study. Drugs Aging 2023;40:153-64.

Fresnais M, Jung I, Klein UB, Miller AK, Turcan S, Haefeli WE, Burhenne J, Longuespée R. Important requirements for desorption/ionization mass spectrometric measurements of temozolomide-induced 2´deoxyguanosine methylations in DNA. Cancers 2023;15:716.

Fresnais M, Liang S, Seven D, Prodanovic N, Sundheimer J, Haefeli WE, Burhenne J, Longuespée R. Desorption kinetics evaluation for the development of validated desorption electrospray ionization-mass spectrometric assays for drug quantification in tissue sections. Int J Mol Sci 2023;24:8469

Hermann SA, Mikus G, Chobanyan-Jürgens K, Gorenflo M, Ziesenitz VC. Pharmacokinetics of a microdosed cocktail of three direct oral anticoagulants in children with congenital heart defects: study protocol for a single-centre clinical trial (DOAC-Child). BMJ Paediatr Open 2023;7:e001662.

Hohmann N, Schröder F, Moreira B, Teng H, Burhenne J, Bruckner T, Mueller S, Haefeli WE*, Seitz HK*. Effect of clomethiazole vs. clorazepate on hepatic fat and serum transaminase activities in alcohol-associated liver disease: results from a randomized, controlled phase II clinical trial. Alcohol Alcohol 2023;58:134-41. *equal contribution

Jungreithmayr V, Haefeli WE, Seidling HM, Implementation Team. Workflow, time requirement, and quality of medication documentation with or without a computerized physician order entry system—a simulation-based lab study. Methods Inf Med 2023;62:40-8.

Longuespée R, Theile D, Zörnig I, Hassel JC, Lindner JR, Haefeli WE, Fresnais M. Molecular prediction of clinical response to anti-PD-1/anti-PD-L1 immune checkpoint inhibitors: New perspectives for precision medicine and mass spectrometry-based investigations. Int J Cancer 2023;153:252-64.

Marok FZ, Wojtyniak J-G, Fuhr LM, Selzer D, Schwab M, Weiss J, Haefeli WE, Lehr T. A physiologically based pharmacokinetic model of ketoconazole and its metabolites as drug-drug interaction perpetrators. Pharmaceutics 2023;15:679.

Meid AD, Wirbka L, Moecker R, Ruff C, Weissenborn M, Haefeli WE, Seidling HM, ARMIN-Studienteam. Mortalität und Hospitalisierungen von Patienten mit interprofessionellem Medikationsmanagement: Resultate der Arzneimittelinitiative Sachsen-Thüringen (ARMIN). Dtsch Arztebl Int. 2023;120:253-60.

Morath C, Schaier M, Ibrahim E, Wang L, Kleist C, Opelz G, Süsal C, Ponath G, Aly M, Alvarez C, Kälble F, Speer C, Benning L, Nusshag C, da Silva LP, Sommerer C, Hückelhoven-Krauss A, Czock D, Mehrabi A, Schwab C, Waldherr R, Schnitzler P, Merle U, Tran TH, Scherer S, Boehmig G, Müller-Tidow C, Reiser J, Schmitt A, Zeier M, Schmitt M, Terness P, Daniel V. Induction of long-lasting regulatory B lymphocytes by modified immune cells in kidney transplant recipients. J Am Soc Nephrol 2023;34:160-74.

Nilles J, Weiss J, Sauter M, Haefeli WE, Ruez S, Theile D. Comprehensive in vitro analysis evaluating the variable drug-drug interaction risk of rifampicin compared to rifabutin. Arch Toxicol 2023;97:2219-30.

Oliveira, C, Longuespee, R. MALDImID: Spatialomics R package and Shiny app for more specific identification of MALDI imaging proteolytic peaks using LC-MS/MS-based proteomic biomarker discovery data. Proteomics 2023;23:e2300005.

Sigaud R*, Rösch L*, Gatzweiler C*, Benzel J*, von Soosten L*, Peterziel H, Selt F, Najafi S, Ayhan S, Gerloff XF, Hofmann N, Büdenbender I, Schmitt L, Foerster KI, Burhenne J, Haefeli WE, Korshunov A, Sahm F, van Tilburg CM, Jones DTW, Pfister SM, Knoerzer D, Kreider BL, Sauter M*, Pajtler KW*, Zuckermann M*, Oehme I*, Witt O*, Milde T*. The first-in-class ERK inhibitor ulixertinib shows promising activity in mitogen-activated protein kinase (MAPK)-driven pediatric low-grade glioma models. Neuro-Oncology 2023;25:566-79.*equal contribution

van Leuven J, Evans S, Kichenadasse G, Steeghs N, Bonevski B, Mikus G, van Dyk M. Framework for implementing individualised dosing of anti-cancer drugs in routine care: overcoming the logistical challenges. Cancers 2023;15:3293.

Wedemeyer H, Schöneweis K, Bogomolov P, Blank A, Voronkova N, Stepanova T, Sagalova O, Chulanov V, Osipenko M, Morozov V, Geyvandova N, Sleptsova S, Bakulin IG, Khaertynova I, Rusanova M, Pathil A, Merle U, Bremer B, Allweiss L, Lempp FA, Port K, Haag M, Schwab M, Schulze zur Wiesch J, Cornberg M, Haefeli WE, Dandri M, Alexandrov A, Urban S. A multicentre, randomised, parallel-group, open-label phase 2 clinical trial (MYR202) to assess safety and efficacy of bulevirtide in combination with tenofovir disoproxil fumarate in patients with HBV/HDV coinfection. Lancet Infect Dis 2023;23:117-129.

Zhu V, Burhenne J, Weiss J, Haag M, Hofmann U, Schwab M, Urban S, Mikus G, Czock D, Haefeli WE, Blank A. Evaluation of the drug-drug interaction potential of the novel hepatitis B and D virus entry inhibitor bulevirtide at OATP1B in healthy volunteers. Front Pharmacol 2023;14:1128547.

Buchbeiträge/Book contributions:

Czock D, Haefeli WE. Kapitel 3.7 Medikamente und die Nebenwirkungen des Klimawandels. In C. Nikendei C, Bugaj TJ, Cranz A, Herrmann A, Tabatabai J, Nikendei F. Heidelberger Standards der Klimamedizin. Heidelberg: HeiCuMed; 2022, pp. 96-102.

Haefeli E. Häufige Arzneimittelinteraktionen  - ein Fokus auf Multikinase-Inhibitoren. In: Lehmann L, Bokemeyer C, Müller OL, Herausgeber. Kardioonkologie. Berlin/Boston: Walter de Gruyter GmbH; 2023; S. 367-380.

Haefeli WE. Arzneimittelanamnese. In: Ärztekammer Nordrhein. Kommunikation im medizinischen Alltag. Ein Leitfaden für die Praxis. Düsseldorf: Ärztekammer Nordrhein; 2023, pp. 48-9.

Publikationen im Druck/Publications in Press:

Breithaupt MH, Krohmer E, Taylor L, Körner E, Hoppe-Tichy T, Burhenne J, Foerster KI, Dachtler M, Huber G, Venkatesh R, Eggenreich K, Czock D, Mikus G, Blank A, Haefeli WE. Time course of CYP3A activity during and after metamizole (dipyrone) in healthy volunteers. Br J Clin Pharmacol, in press

Fresnais M, Jung I, Klein UB, Theile D, Liang S, Haefeli WE, Burhenne J, Longuespée R. Quantification of biologically-active DNA alkylation in temozolomide-exposed glioblastoma cell lines by ultra-performance liquid chromatography-tandem mass spectrometry: method development and recommendations for validation. ACS Omega, in press

Kluwe F, Michelet R, Huisinga W, Zeitlinger M, Mikus G, Kloft C. Towards model-informed precision dosing of voriconazole: Challenging published voriconazole nonlinear mixed-effects models with real-world clinical data. Clin Pharmacokinet, in press

Kühn T, Speer C, Morath C, Bartenschlager M, Kim H, Beimler J, Buylaert M, Nusshag C, Kälble F, Reineke M, Töllner M, Klein K, Blank A, Parthé S, Schnitzler P, Zeier M, Süsal C, Bartenschlager R, Tran TH, Schaier M, Benning L. Immune response to COVID-19 mRNA vaccination in previous non-responder kidney transplant recipients after short-term withdrawal of mycophenolic acid one- and three-months after an additional vaccine dose. Transplantation, in press

Lenard A, Hermann SA, Stoll F, Burhenne J, Foerster KI, Mikus G, Meid AD, Haefeli WE, Blank A. Effect of clarithromycin, a strong CYP3A and P-glycoprotein inhibitor, on the pharmacokinetics of edoxaban in healthy volunteers and the evaluation of the drug interaction with other oral factor Xa inhibitors by a microdose cocktail approach. Cardiovasc Drugs Ther, in press

Morath B, Meid AD, Zaradzki M, Geßele C, Nüse S, Chiriac U, Hoppe-Tichy T, Karck M, Soethoff J. Analysing and improving pre-operative medication management in cardiac surgery. Br J Clin Pharmacol, in press

Muhareb A, Blank A, Meid AD, Foerster KI, Stoll F, Burhenne J, Haefeli WE, Mikus G. CYP3A and CYP2C19 activity determined by microdosed probe drugs accurately predict voriconazole clearance in healthy adults. Clin Pharmacokin 2023, in press

Schaier M, Morath C, Wang L, Kleist C, Opelz G, Tran TH, Scherer S, Pham L, Ekpoom N, Süsal C, Ponath G, Kälble F, Speer C, Benning L, Nusshag C, Mahler CF, Pego Da Silva L, Sommerer C, Hückelhoven-Krauss A, Czock D, Mehrabi A, Schwab C, Waldherr R, Schnitzler P, Merle U, Schwenger V, Krautter M, Kemmner S, Fischereder M, Stangl M, Hauser IA, Böhmig G, Müller-Tidow C, Reiser J, Zeier MG, Schmitt M, Terness P, Schmitt A, Daniel V. Five-year follow-up of a phase I trial of donor-derived modified immune cell infusion in kidney transplantation. Front Immunol 2023, in press

Theile D, Nilles J, Meid AD. Physiology-based pharmacokinetic modelling and experimental data suggest that rifabutin alters dolutegravir kinetics by both P-glycoprotein induction and concurrent inhibition. Br J Clin Pharmacol, in press

Thomson-Luque R, Rosenkranz M, Fürle K, Hibbert J, Ulmer A, Ali A, Giese T, Blank A, Haefeli WE, Böhnlein E, Lanzer M. Multifunctional IgG/IgM antibodies and cellular cytotoxicity are elicited by the full-length MSP1 “SumayaVac-1” malaria vaccine in a phase I clinical trial. NPJ Vaccines 2023, in press

Alborzinia H, Flórez AF, Kreth S, Brückner LM, Yildiz U, Gartlgruber M, Odoni DI, Poschet G, Garbowicz K, Shao C, Klein C, Meier J, Zeisberger P, Nadler-Holly M, Ziehm M, Paul F, Burhenne J, Bell E, Shaikhkarami M, Würth R, Stainczyk SA, Wecht EM, Kreth J, Büttner M, Ishaque N, Schlesner M, Nicke B, Stresemann C, Llamazares-Prada M, Reiling JH, Fischer M, Amit I, Selbach M, Herrmann C, Wölfl S, Henrich KO, Höfer T, Trumpp A, Westermann F. MYCN mediates cysteine addiction and sensitizes neuroblastoma to ferroptosis. Nat Cancer 2022;3:471-485.

Alexovic M, Lindner JR, Bober P, Longuespée R, Sabo J, Davalieva K. Human peripheral blood mononuclear cells: a review of recent proteomic applications. Proteomics 2022, e2200026.

Amelung S, Czock D, Thalheimer M, Hoppe-Tichy T, Haefeli WE, Seidling HM. Shortcomings of administrative data to derive preventive strategies for inhospital drug-induced acute kidney failure - insights from patient record analysis. J Clin Med 2022;11:4285.

Bajraktari-Sylejmani G, Linde T, Burhenne J, Haefeli WE, Sauter M*, Weiss J*. Evaluation of PepT1 (SLC15A1) substrate characteristics of therapeutic cyclic peptides. Pharmaceutics 2022;14:1610. *equal contribution.

Bay C*, Bajraktari-Sylejmani G*, Haefeli WE, Burhenne J, Weiss J, Sauter M. Functional characterization of the solute carrier LAT-1 (SLC7A5/SLC2A3) in human brain capillary endothelial cells with rapid UPLC-MS/MS quantification of intracellular isotopically labeled L-leucine. Int J Mol Sci 2022;23:3637. * equal contribution.

Benning L, Morath C, Kühn T, Bartenschlager M, Kim H, Beimler J, Buylaert M, Nusshag C, Kälble F, Reineke M, Töllner M, Schaier M, Klein K, Blank A, Schnitzler P, Zeier M, Süsal C, Bartenschlager R, Tran TH and Speer C. Humoral response to SARS-CoV-2 mRNA vaccination in previous non-responder kidney transplant recipients after short-term withdrawal of mycophenolic acid. Front Med 2022;9:958293.

Bittmann JA, Haefeli WE, Seidling HM. Modulators influencing medication alert acceptance: an exploratory review. Appl Clin Inform 2022;13:468-485.

Blank A, Hohmann N, Dettmer M, Manka-Stuhlik A, Mikus G, Stoll F, Stützle-Schnetz M, Thomas D, Exner E, Schmitt-Bormann B, Schaller T, Laage R, Schönborn-Kellenberger O, Arndt M, Haefeli WE, Krauss J. First-in-human, randomized, double-blind, placebo-controlled, dose escalation trial of the anti-herpes simplex virus monoclonal antibody HDIT101 in healthy volunteers. Clin Transl Sci 2022;15:2366-2377.

Boettcher M, Duengen HD, Donath F, Mikus G, Werner N, Thuermann PA, Karakas M, Besche N, Koch T, Gurniak M, Becker C. Vericiguat in combination with short-acting nitroglycerin in patients with chronic coronary syndromes: the randomized, phase Ib, VENICE study. Clin Pharmacol Ther 2022;111:1239-1247.

Breithaupt MH, Krohmer E, Taylor L, Koerner E, Hoppe-Tichy T, Burhenne J, Foerster KI, Dachtler M, Huber G, Venkatesh R, Eggenreich K, Czock D, Mikus G, Blank A, Haefeli WE. Oral bioavailability of microdoses and therapeutic doses of midazolam as a 2-dimensionally printed orodispersible film in healthy volunteers. Eur J Clin Pharmacol 2022;78:1965-1972.

Cardona MI, Weißenborn M, Zöllinger I, Kroeber ES, Bauer A, Luppa M, Pabst A, Czock D, König HH, Wiese B, Gensichen J, Frese T, Kaduszkiewicz H, Hoffmann W, Riedel-Heller SG, Thyrian JR. Physical activity determinants in older German adults at increased dementia risk with multimorbidity: baseline results of the AgeWell.de study. Int J Environ Res Public Health 2022;19:3164.

Carotti V*, Rigalli JP*, van Asbeck-van der Wijst J, Hoenderop JGJ. Interplay between purinergic signalling and extracellular vesicles in health and disease. Biochem Pharmacol 2022;203:115192. * equal contribution.

Carotti V, van der Wijst J, Verschuren EHJ, Rutten L, Sommerdijk N, Kaffa C, Sommers V, Rigalli JP, Hoenderop JGJ. Involvement of ceramide biosynthesis in increased extracellular vesicle release in Pkd1 knock out cells. Front Endocrinol 2022;13:1005639.

Czock D, Keller F. Clinical pharmacokinetics and pharmacodynamics of roxadustat. Clin Pharmacokinet 2022;61:347-362.

Dreischulte T, Shahid F, Muth C, Schmiedl S, Haefeli WE. Prescription cascades - detect, prevent, consciously use. Dtsch Arztebl Int 2022;119:745-752.

Eidam A, Roth A, Frick E, Metzner M, Lampert A, Seidling HM, Haefeli WE, Bauer JM. Development of an electronic tool to assess patient preferences in geriatric polypharmacy (PolyPref). Patient Prefer Adherence 2022;16:1733-1747.

Elbe A, Foerster KI, Blank A, Rose P, Burhenne J, Haefeli WE, Mikus G. Evaluation of CYP2C19 activity using microdosed oral omeprazole in humans. Eur J Clin Pharmacol 2022;78:975-987.

Fresnais M, Karabulut S, Zeed YA, Ungermann J, Benzel J, Pajtler KW, Pfister SM, Haefeli WE, Burhenne J, Longuespée R. Important requirements for the selection of internal standards during the development of desorption/ionization assays for drug quantification in biological matrices - A practical example. Molecules 2022;27:690.

Fresnais M, Turcan S, Theile D, Ungermann J, Zeed YA, Lindner JR, Breitkopf M, Burhenne J, Haefeli WE, Longuespée R. Approaching sites of action of temozolomide for pharmacological and clinical studies in glioblastoma. Biomedicines 2022;10:1.

Fresnais M, Liang S, Breitkopf M, Lindner JR, Claude E, Pringle S, Levkin PA, Demir K, Benzel J, Sundheimer J, Statz B, Pajtler KW, Pfister SM, Haefeli WE, Burhenne J, Longuespée R. Analytical performance evaluation of new DESI enhancements for targeted drug quantification in tissue sections. Pharmaceuticals 2022;15:694.

Gerharz A*, Ruff C*, Wirbka L, Stoll F, Haefeli WE, Groll A, Meid AD. Predicting hospital readmissions from health insurance claims data: a modeling study targeting potentially inappropriate prescribing. Meth Inf Med 2022;61:55-60. * equal contribution.

Gillot L, Lebeau A, Baudin L, Pottier C, Louis T, Durre T, Longuespée R, Mazzucchelli G, Nizet C, Blacher S, Kridelka F, Noel A. Periostin in lymph node pre-metastatic niches governs lymphatic endothelial cell functions and metastatic colonization. Cell Mol Life Sci 2022;79:295.

Haefeli WE. Oral pharmacotherapy in COVID-19. interaction management when using nirmatrelvir/ritonavir. Conclusion. Dtsch Arztebl Int. 2022;119:761-762.

Hohmann N, Schröder F, Moreira B, Teng H, Burhenne J, Bruckner T, Mueller S, Haefeli WE, Seitz HK. Clomethiazole inhibits cytochrome P450 2E1 and improves alcoholic liver disease. Gut 2022;71:842-844.

Hoiem TS, Andersen MK, Martin-Lorenzo M, Longuespée R, Claes BSR, Nordborg A, Dewez F, Balluff B, Giampà M, Sharma A, Hagen L, Heeren RMA, Bathen TF, Giskeodegard GF, Krossa S, Tessem MB. An optimized MALDI MSI protocol for spatial detection of tryptic peptides in fresh frozen prostate tissue. Proteomics 2022; e2100223.

Jost F, Theile D. Interaction between proton pump inhibitors and checkpoint inhibitors. MMP 2022;45:344-350.

Kama K, La Rosée P, Czock D, Ships JB, Illerhaus G. Hemophagocytic syndrome-associated intravascular large B-cell lymphoma with dialysis-dependent end-stage renal disease treated with autologous stem cell transplantation using a modified TEAM regimen. Cureus 2022.e25885. Kraft M, Foerster KI, Wiedmann F, Sauter M, Paasche A, Blochberger PL, Yesilgöz B, L'hoste Y, Frey N, Haefeli WE, Burhenne J, Schmidt C. Simultaneous quantification and pharmacokinetic characterization of doxapram and 2-ketodoxapram in porcine plasma and brain tissue. Pharmaceutics 2022;14:762.

Kuznia S, Czock D, Kopp-Schneider A, Caspari R, Fischer H, Laetsch DC, Slavic M, Brenner H, Schöttker B. Efficacy and safety of a personalized vitamin D3 loading dose followed by daily 2,000 IU in colorectal cancer patients with vitamin D insufficiency. Nutrients 2022;14:4546.

Meid A, Gerharz A, Groll A. Machine learning for tumor growth inhibition: interpretable predictive models for transparency and reproducibility. CPT Pharmacometrics Syst Pharmacol 2022;11:257-261. Meid AD, Wirbka L, ARMIN Study Group, Groll A, Haefeli WE. Can machine learning from real-world data support drug treatment decisions? A prediction modeling case for direct oral anticoagulants. Med Decis Making 2022;42:587-598. Mikus G, Foerster KI, Terstegen T, Vogt C, Said A, Schulz M, Haefeli WE. Oral drugs against COVID-19 - Management of drug interactions with the use of nirmatrelvir/ritonavir. Dtsch Arztebl Int 2022;119:263-269.

Moecker R, Terstegen T, Haefeli WE, Seidling HM. Erratum to "The influence of intervention complexity on barriers and facilitators in the implementation of professional pharmacy services - A systematic review" [Res Soc Adm Pharm 17/10 (2021) 1651-1662]. Res Social Adm Pharm 2022;18:2909-2911.

Moecker R, Weissenborn M, Klingenberg A, Wirbka L, Fuchs A, Eickhoff C, Mueller U, Schulz M, Kaufmann-Kolle P, Haefeli WE, Seidling HM. Task sharing in an interprofessional medication management program - a survey of general practitioners and community pharmacists. BMC Health Serv Res 2022;22:1005.

Moecker R, Fuchs A, ARMIN Study Group, Haefeli WE, Weissenborn M*, Seidling HM*. Attitudes of non-participating general practitioners and community pharmacists towards interprofessional medication management in primary care - an interview study. Int J Clin Pharm 2022;44:1380-1393. *equal contribution.

Morath B, Lampert A, Glaß FE, Metzner M, Study Team D, Haefeli WE, Seidling HM. Changing the medication documentation process for discharge: impact on clinical routine and documentation quality - a process analysis. Eur J Hosp Pharm 2022;29:33-39.

Morath C, Schmitt A, Schmitt M, Wang L, Kleist C, Opelz G, Süsal C, Tran TH, Scherer S, Schwenger V, Kemmner S, Fischereder M, Stangl M, Hauser IA, Sommerer C, Nusshag C, Kälble F, Speer C, Benning L, Bischofs C, Sauer S, Schubert ML, Kunz A, Hückelhoven-Krauss A, Neuber B, Mehrabi A, Schwab C, Waldherr R, Czock D, Böhmig GA, Reiser J, Roers A, Müller-Tidow C, Terness P, Zeier M, Daniel V, Schaier M. Individualized immunosuppression with intravenously administered donor-derived modified immune cells compared with standard of care in living donor kidney transplantation (TOL-2 Study): protocol for a multicenter, open-label, phase II, randomized controlled trial. BMJ Open 2022;12:e066128.

Nassar YM*, Hohmann N*, Michelet R, Gottwalt K, Meid AD, Burhenne J, Huisinga W, Haefeli WE, Mikus G**, Kloft C**. Quantification of the time course of CYP3A inhibition, activation, and induction using a population pharmacokinetic model of microdosed midazolam continuous infusion. Clin Pharmacokinet 2022;61:1595-1607. *and**equal contribution.

Nielsen PB, Melgaard L, Overvad TF, Jensen M, Larsen TB, Lip GYH. Risk of cerebrovascular events in intracerebral hemorrhage survivors with atrial fibrillation: a nationwide cohort study. Stroke 2022;53:2559-2568.

Nilles J, Weiss J, Haefeli WE, Ruez S, Theile D. How to avoid misinterpretation of dual reporter gene assay data affected by cell damage. Arch Toxicol 2022;96:2501-10.

Nilles J, Weiss J. Theile D. Crystal violet staining is a reliable alternative to bicinchoninic acid assay-based normalization. Biotechniques 2022;73:131-135.

Rizos T*, Meid AD*, Huppertz A*, Dumschat C, Purrucker J, Foerster KI, Burhenne J, Czock D, Jenetzky E, Ringleb PA, Haefeli WE. Low exposure to direct oral anticoagulants is associated with ischemic stroke and its severity. J Stroke 2022;24:88-97. * equal contribution.

Rohr BS, Foerster KI, Blank A, Burhenne J, Mahmoudi M, Haefeli WE, Mikus G. Perpetrator characteristics of azole antifungal drugs on three oral factor Xa inhibitors administered as microdosed cocktail. Clin Pharmacokinet 2022;61:97-109.

Schulz J, Thomas A, Saleh A, Michelet R, Mikus G, Kloft C. Towards the elucidation of voriconazole pharmacokinetics: a quantitative characterization of its metabolism. Pharmaceutics 2022;14:477.

Schulz J, Michelet R, Joseph JF, Zeitlinger M, Schumacher F, Mikus G, Kloft C. A versatile high-performance LC-MS/MS assay for the quantification of voriconazole and its N-oxide metabolite in small sample volumes of multiple human matrices for biomedical applications. J Pharm Biomed Anal 2022;210:114551.

Schulz J, Michelet R, Zeitlinger M, Mikus G, Kloft C. Microdialysis of drug and drug metabolite: a comprehensive in vitro analysis for voriconazole and voriconazole N-oxide. Pharm Res 2022;39:2991-3003.

Stoll F, Blank A, Mikus G, Czock D, Foerster KI, Hermann S, Gümüs K, Muhareb A, Hummler S, Sauter M, Weiss J, Burhenne J, Haefeli WE. Effect of pantoprazole on the absorption of hydroxychloroquine - a randomized drug-drug interaction trial in healthy adults. Clin Pharmacol Drug Dev 2022;11:285-290.

Stoll F, Eidam A, Michael L, Bauer JM, Haefeli WE. Drug treatment of hypercholesterolemia in older adults: focus on newer agents. Drugs Aging 2022;39:251-256.

Stoll F, Seidel-Glätzer A, Burghaus I, Göring O, Sauter M, Rose P, Daniel V, Haag M, Schwab M, Riffel J, Andre F, Taylor L, Weiss J, Burhenne J, Cleeves V, Haefeli WE, Blank A. Metabolic effect of blocking sodium-taurocholate co-transporting polypeptide in hypercholesterolemic humans with a twelve-week course of bulevirtide - an exploratory phase I clinical trial. Int J Mol Sci 2022;23:15924.

Stoll F, Uslu R, Blessing E, Frey N, Katus HA, Erbel C, Heilmeier B, Müller OJ. Drug-coated balloons in below-the-knee arteries - analysis of a real-world data set. VASA 2022;51:256-262.

Weiss J, Foerster KI, Weber M, Burhenne J, Mikus G, Lehr T, Haefeli WE. Does the circulating ketoconazole metabolite N-deacetyl ketoconazole contribute to the drug-drug interactions potential of the parent compound? Eur J Pharm Sci 2022;169:106076.

Wendel F, Bauer A, Blotenberg I, Brettschneider C, Buchholz M, Czock D, Döhring J, Escales C, Frese T, Hoffmann W, Kaduszkiewicz H, König HH, Löbner M, Luppa M, Schwenker R, Thyrian JR, Weißenborn M, Wiese B, Zöllinger I, Riedel-Heller S, Gensichen J. Social network and social participation in elderly primary care patients in Germany and associations with depressive symptoms - a cross sectional analysis from the AgeWell.de study. J Clin Med 2022;11:5940.

Wiedmann F, Beyersdorf C, Zhou X-B, Kraft M, Paasche A, Jávorszky N, Rinné S, Sutanto H, Büscher A, Foerster KI, Blank A, El-Battrawy I, Li X, Lang S, Tochtermann U, Kremer J, Arif R, Karck M, Decher N, van Loon G, Akin I, Borggrefe M, Kallenberger S, Heijman J, Haefeli WE, Katus HA, Schmidt C. Treatment of atrial fibrillation with doxapram: TASK 1 potassium channel inhibition as a novel pharmacological strategy. Cardiovasc Res 2022;118:1728-1741.

Wirbka L, Ruff C, Haefeli WE, Meid AD. A prediction model for nonpersistence or nonadherence to direct oral anticoagulants in hospitalized patients with atrial fibrillation. J Manag Care Spec Pharm 2022;28:1161-1172.

Wurmbach VS, Schmidt SJ, Lampert A, Bernard S, Meid AD, Frick E, Metzner M, Wilm S, Mortsiefer A, Bücker B, Altiner A, Sparenberg L, Szecsenyi J, Peters-Klimm F, Kaufmann-Kolle P, Thürmann PA, Haefeli WE, Seidling HM. Prevalence and patient-rated relevance of complexity factors in medication regimens of community-dwelling patients with polypharmacy. Eur J Clin Pharmacol 2022;78:1127-1136.

Wurmbach VS, Schmidt SJ, Lampert A, Bernard S, Meid AD, Frick E, Metzner M, Wilm S, Mortsiefer A, Bücker B, Altiner A, Sparenberg L, Szecsenyi J, Peters-Klimm F, Kaufmann-Kolle P, Thürmann PA, Seidling HM, Haefeli WE. HIOPP-6 - a pilot study on the evaluation of an electronic tool to assess and reduce the complexity of drug treatment considering patients' views. BMC Prim Care 2022;23:164.

Aklillu E, Zumla A, Habtewold A, Amogne W, Makonnen E, Yimer G, Burhenne J, Diczfalusy U. Early or deferred initiation of efavirenz during rifampicin-based TB therapy has no significant effect on CYP3A induction in TB-HIV infected patients. Br J Pharmacol 2021;178:3294-3308.

Alexovic M, Sabo J, Longuespée R. Microproteomic sample preparation. Proteomics 2021:e2000318.

Alexovic M, Sabo J, Longuespée R. Automation of single-cell proteomic sample preparation. Proteomics 2021;e2100198.

Benzel J, Bajraktari-Sylejmani G, Uhl P, Davis A, Nair S, Pfister S, Haefeli WE, Weiss J, Burhenne J, Pajtler KW, Sauter M. Investigating the central nervous system disposition of actinomycin D: Implementation and evaluation of cerebral microdialysis and brain tissue measurements supported by UPLC-MS/MS quantification. Pharmaceutics 2021;13:1498.

Bieber M, Foerster KI, Haefeli WE, Pham M, Schuhmann MK, Kraft P. Treatment with edoxaban attenuates acute stroke severity in mice by reducing blood-brain barrier damage and inflammation. Int J Mol Sci 2021;22:9893.

Bittmann JA, Rein EK, Metzner M, Haefeli WE, Seidling HM. The acceptance of interruptive medication alerts in an electronic decision support system differs between different alert types. Methods Inf Med 2021;60:180-184.

Ceré LI, Sedlmeier MG, Semeniuk M, Luquita MG, Francés D, Ronco MT, Rigalli JP, Ruiz ML, Catania VA. Induction of P-glycoprotein expression and activity by prolactin in female rat liver. Life Sci 2021;287:119936.

Dinh TS, González-González AI, Meid AD, Snell KIE, Rudolf H, Brueckle M-S, Blom JW, Thiem U, Trampisch H-J, Elders PJM, Donner-Banzhoff N, Gerlach FM, Harder S, van den Akker M, Glasziou PP, Haefeli WE, Muth C. Are anticholinergic symptoms a risk factor for falls in elderly general practice patients with polypharmacy? Study protocol for the development and validation of a prognostic model. Front Pharmacol 2021;11:577747.

Dominguez CJ, Tocchetti GN, Rigalli JP, Mottino AD. Acute regulation of apical ABC transporters in the gut. Potential influence on drug bioavailability. Pharmacol Res 2021;163:105251.

Fresnais M, Yildirim E, Karabulut S, Jäger D, Zörnig I, Benzel J, Pajtler K, Pfister S, Burhenne J, Haefeli WE, Longuespée R. Rapid MALDI-MS assays for drug quantification in biological matrices: lessons learned, new developments, and future perspectives. Molecules 2021;26:1281.

Fresnais M, Burhenne J, Haefeli WE, Longuespée R. Desorption/ionization-MS methods for drug quantification in biological matrices and their validation following regulatory guidance. Anal Chem 2021;93:7152-7163.

González-González AI, Meid AD, Dinh TS, Blom JW, van den Akker M, Elders PJ, Thiem U, Küllenerg De Gaudry D, Swart KMA, Rudolf H, Bosch-Lenders D, Trampisch HJ, Meerpohl JJ, Gerlach FM, Flaig B, Kom G, Snell KIE, Perera R, Haefeli WE, Glasziou PP, Muth C. A prognostic model predicted deterioration in health-related quality of life in older patients with multimorbidity and polypharmacy. J Clin Epidemiol 2021;130:1-12.

González-González AI, Dinh TS, Meid AD, Blom JW, van den Akker M, Elders PJM, Thiem U, Kuellenberg de Gaudry D, Snell KIE, Perera R, Swart KMA, Rudolf H, Bosch-Lenders D, Trampisch HJ, Meerpohl JJ, Flaig B, Kom G, Gerlach FM, Hafaeli WE, Glasziou PP, Muth C. Predicting negative health outcomes in older general practice patients with chronic illness: rationale and development of the PROPERmed harmonized individual participant data database. Mech Ageing Dev 2021;194:111436.

Grass J, Rose P, Burhenne J, Blank A, Haefeli WE, Mikus G. Absolute Bioavailability of Microdosed Midazolam After Buccal Administration Is Dependent on Buccal Exposure Time. J Clin Pharmacol 2021;61:472-479.

Halling T, Akkermann S, Löffler F, Groh A, Heitland I, Haefeli WE, Bauersachs J, Kahl KG, Westhoff-Bleck M. Factors that influence adherence to medication in adults with congenital heart disease (ACHD). Front Psychiatry 2021;12:788013.

Hein M, Chobanyan-Jürgens K, Tegtbur U, Engeli S, Jordan J, Haufe S. Effect of normobaric hypoxic exercise on blood pressure in old individuals. Eur J Appl Physiol 2021;121:817-825.

Hohmann N, Bozorgmehr F, Christopoulos P, Mikus G, Blank A, Burhenne J, Thomas M, Haefeli WE. Pharmacoenhancement of low crizotinib plasma concentrations in patients with anaplastic lymphoma kinase-positive non-small cell lung cancer using the CYP3A inhibitor cobicistat. Clin Transl Sci 2021;14:487-491.

Huppertz A, Bollmann J, Behnisch R, Bruckner T, Zorn M, Burhenne J, Haefeli WE, Czock D. Differential effect of a continental breakfast on tacrolimus formulations with different release characteristics. Clin Pharmacol Drug Dev 2021;10:899-907.

Jungreithmayr V, Meid AD, Implementation Team, Haefeli WE, Seidling HM. The impact of a computerized physician order entry system implementation on 20 different criteria of medication documentation - a before-and-after study. BMC Med Inform Decis Mak 2021;21:279.

Kazdal D, Rempel E, Oliveira C, Allgauer M, Harms A, Singer K, Kohlwes E, Ormanns S, Fink L, Kriegsmann J, Leichsenring M, Kriegsmann K, Stogbauer, F, Tavernar L, Leichsenring J, Volckmar AL, Longuespee R, Winter H, Eichhorn M, Heussel CP, Herth F, Christopoulos P, Reck M, Muley T, Weichert W, Budczies J, Thomas M, Peters S, Warth A, Schirmacher P, Stenzinger A, Kriegsmann M. Conventional and semi-automatic histopathological analysis of tumor cell content for multigene sequencing of lung adenocarcinoma. Transl Lung Cancer Res 2021;10:1666-1678.

Kluwe F, Michelet R, Mueller-Schoell A, Maier C, Klopp-Schulze L, van Dyk M, Mikus G, Huisinga W, Kloft C. Perspectives on Model-Informed Precision Dosing in the Digital Health Era: Challenges, Opportunities, and Recommendations. Clin Pharmacol Ther 2021;109:29.

Kraft M, Büscher A, Wiedmann F, L'hoste Y, Haefeli WE, Frey N, Katus HA, Schmidt C. Current drug treatment strategies for atrial fibrillation and TASK-1 inhibition as an emerging novel therapy option. Front Pharmacol 2021;12:638445.

Kulyyassov A, Fresnais M, Longuespée R. Targeted liquid chromatography-tandem mass spectrometry analysis of proteins: basic principles, applications, and perspectives. Proteomics 2021;e2100153.

Kusch MKP, Haefeli WE, Seidling HM. Customization of information on adverse drug reactions according to patients' needs - a qualitative study. Patient Educ Couns 2021;104:2351-2357.

Longuespée R, Theile D, Fresnais M, Burhenne J, Weiss J, Haefeli WE. Approaching sites of action of drugs in clinical pharmacology: new analytical options and their challenges. Br J Clin Pharmacol 2021;87:858-874.

Luis G, Godfroid A, Nishiumi S, Cimino J, Blacher S, Maquoi E, Wery C, Collignon A, Longuespée R, Montero-Ruiz L, Dassoul I, Maloujahmoum N, Pottier C, Mazzucchelli G, Depauw E, Bellahcène A, Yoshida M, Noel A, Sounni NE. Tumor resistance to ferroptosis driven by stearoyl-CoA desaturase-1 (SCD1) in cancer cells and fatty acid binding protein-4 (FABP4) in tumor microenvironment promote tumor recurrence. Redox Biol 2021;43:102006.

Mahmoudi M, Foerster KI, Burhenne J, Weiss J, Mikus G, Haefeli WE. Application of microdosed intravenous omeprazole to determine hepatic CYP2C19 activity. J Clin Pharmacol 2021;61:789-798.

Meid AD, González-González AI, Dinh TS, Blom JW, van den Akker M, Elders PJM, Thiem U, Küllenberg de Gaudry D, Swart KMA, Rudolf H, Bosch-Lenders D, Trampisch HJ, Meerpohl JJ, Gerlach FM, Flaig B, Kom G, Snell KIE, Perera R, Haefeli WE, Glasziou PP, Muth C. Predicting hospital admissions from individual patient data (IPD): an applied example to explore key elements driving external validity. BMJ Open 2021;11:e045572.

Meid A. Teaching reproducible research for medical students and postgraduate pharmaceutical scientists. BMC Res Notes 2021;14:445.

Moecker R, Terstegen T, Haefeli WE, Seidling HM. The influence of intervention complexity on barriers and facilitators in the implementation of professional pharmacy services - a systematic review. Res Soc Admin Pharm 2021;17:1651-62.

Morath B*, Meid AD*, Rickmann J, Soethoff J, Verch M, Karck M, Zaradzki M. Renal safety of hydroxyethyl starch 130/0.42 after cardiac surgery: a retrospective cohort analysis. Drug Saf 2021;44:1311-1321.

Mueller-Schoell A, Michelet R, Klopp-Schulze L, van Dyk M, Mürdter T, Schwab M, Joerger M, Huisinga W, Mikus G, Kloft C. Computational treatment simulations to assess the need for personalized tamoxifen dosing in breast cancer patients of different biogeographical groups. Cancers 2021;13:2432.

Mueller-Schoell A, Michelet R, Weinelt F, Kloft C, Mikus G. CYP2D6 phenotype explains reported yohimbine concentrations in four severe acute intoxications. Arch Toxicol 2021;95:2867-2870.

Rengelshausen J, Breithaupt-Groegler K, Donath F, Erb-Zohar K, Hardman T, Mikus G, Plassmann S, Wensing G, Sourgens H. How to interpret an investigator's brochure for meaningful risk assessment: results of an AGAH discussion forum. Ther Innov Regul Sci 2021;55:612-618.

Rigalli JP, Theile D, Nilles J, Weiss J. Regulation of PXR function by coactivator and corepressor proteins: ligand binding is just the beginning. Cells 2021;10:3137.

Röhr S, Zülke A, Luppa M, Brettschneider C, Weißenborn M, Kühne F, Zöllinger I, Samos FAZ, Bauer A, Döhring J, Krebs-Hein K, Oey A, Czock D, Frese T, Gensichen J, Haefeli WE, Hoffmann W, Kaduszkiewicz H, König HH, Thyrian JR, Wiese B, G. Riedel-Heller SG. Recruitment and baseline characteristics of participants in the AgeWell.de study - A pragmatic cluster-randomized controlled lifestyle trial against cognitive decline. Int J Environ Res Public Health 2021;18:408.

Ruff C, Gerharz A, Groll A, Stoll F, Wirbka L, Haefeli WE, Meid AD. Disease-dependent variations in the timing and causes of readmissions in Germany: a claims data analysis for six different conditions. PLoS ONE 2021;16:e0250298.

Sauter M, Uhl P, Burhenne J, Haefeli WE. Application of triple quadrupole tandem mass spectrometry to the bioanalysis of collision-induced dissociation-resistant cyclic peptides - Ultra-sensitive quantification of the somatostatin-analog pasireotide utilizing UHPLC-MS/MS.J Pharm Biomed Anal 2021;194:113728.

Sauter M, Foerster KI, Benzel J, Pfister S, Pajtler KW, Haefeli WE, Burhenne J. Bioanalysis of selinexor in mouse plasma micro-samples utilizing UPLC-MS/MS. J Chromatogr B 2021;1176:122781.

Sauter M, Blank A, Stoll F, Lutz N, Haefeli WE, Burhenne J. Intact plasma quantification of the large therapeutic lipopeptide bulevirtide. Anal Bioanal Chem 2021;413:5645-5654.

Schmulenson E, Zimmermann N, Mikus G, Joerger M, Jaehde U. Current status and future outlooks on therapeutic drug monitoring of fluorouracil. Expert Opin Drug Metab Toxicol 2021;12:1407-1422.

Seidling HM, Wien K, Fabricius J, John C, Hauser J, Renner K, Schäfer P, Krisam J, Haefeli WE. Short- and mid-term impact of community pharmacy-based medication reviews on medication- and patient-related outcomes in Germany. Int J Clin Pharmacol Ther 2021;59:188-197.

Semeniuk M, Ceré LI, Ciriaci N, Bucci Muñoz M, Quiroga AD, Luquita MG, Roma S, Catania VA, Mottino AD, Rigalli JP, Ruiz ML. Protective effect of genistein pre-treatment on paraquat hepatotoxicity in rats. Toxicol Appl Pharmacol 2021;426:115636.

Theile D, Wagner L, Haefeli WE, Weiss J. In vitro evidence suggesting that the toll-like receptor 7 and 8 agonist resiquimod (R-848) unlikely affects drug levels of co-administered compounds. Eur J Pharm Sci 2021;162:105826.

Theile D, Wagner L, Bay C, Haefeli WE, Weiss J. Time-resolved effect of interferon-alpha 2a on activities of nuclear factor kappa B, pregnane X receptor, and on drug disposition genes. Pharmaceutics 2021;13:808.

Theile D, Wizgall P. Acquired ABC-transporter overexpression in cancer cells: transcriptional induction or Darwinian selection? Naunyn Schmiedebergs Arch Pharmacol 2021;394:1621-1632.

Toenshoff B, Mueller B, Elling R, Renk H, Meissner P, Hengel H, Garbade S, Kieser M, Jeltsch K, Grulich-Henn J, Euler J, Stich M, Chobanyan-Jürgens K, Zernickel M, Janda A, Woelfle L, Stamminger T, Iftner T, Ganzenmueller T, Schmitt C, Görne T, Laketa V, Olberg S, Plaszczyca A, Cortese M, Pape C, Remme R, Huzly D, Panning M, Weigang S, Giese S, Ciminski K, Ankerhold J, Kochs G, Schwemmle M, Handgretinger R, Niemeyer C, Engel C, Kern W, Hoffmann G, Franz A, Henneke P, Debatin K-M, Kräusslich H-G. Prevalence of SARS-CoV-2 infection in children and their parents in southwest Germany. JAMA Pediatr 2021;175:586-593.

Uhl P, Sauter M, Hertlein T, Witzigmann D, Laffleur F, Hofhaus G, Fidelj V, Tursch A, Özbek S, Hopke E, Haberkorn U, Bernkop-Schnürch A, Ohlsen K, Fricker G, Mier W. Overcoming the Mucosal Barrier: Tetraether Lipid-Stabilized Liposomal Nanocarriers Decorated with Cell-Penetrating Peptides Enable Oral Delivery of Vancomycin. Adv Ther 2021;4:200247

Von Linde T, Bajraktari-Sylejmani G, Haefeli WE, Burhenne J, Weiss J, Sauter M. Rapid and sensitive quantification of intracellular glycyl-sarcosine for semi-high-throughput screening for inhibitors of PEPT-1. Pharmaceutics 2021;13:1019.

Wagner L, Haefeli WE, Merle U, Lorenz H-M, Hohmann N, Weiss J, Theile D. A nuclear factor kappa B reporter cell line used to evaluate ex vivo the net inflammatory effect of plasma samples from patients with rheumatoid arthritis, psoriasis, or COVID-19. Cytokines 2021;138:155399.

Wass M, Göllner S, Besenbeck B, Schlenk RF, Mundmann P, Göthert JR, Noppeney R, Schliemann C, Mikesch JH, Lenz G, Dugas M, Wermke M, Röllig C, Bornhäuser M, Serve H, Platzbecker U, Foerster KI, Burhenne J, Haefeli WE, Müller LP, Binder M, Pabst C, Müller-Tidow C. A proof of concept phase I/II pilot trial of LSD1 inhibition by tranylcypromine combined with ATRA in refractory/relapsed AML patients not eligible for intensive therapy. Leukemia 2021;35:701-711.

Weiss J, Bajraktari-Sylejmani G, Haefeli WE. Low risk of the TMPRSS2 inhibitor camostat mesylate and its metabolite GBPA to act as perpetrators of drug-drug interactions. Chem Biol Interact 2021;338:109428.

Wiebe ST, Huennemeyer A, Kadus W, Goettel M, Jambrecina A, Schultz A, Vinisko R, Schlieker L, Herich L, Mikus G. Midazolam microdosing applied in early clinical development for drug-drug interaction assessment. Br J Clin Pharmacol 2021;87:178-188.

Wiedmann F, Beyersdorf C, Zhou X-B, Kraft M, Foerster KI, El-Battrawy I, Lang S, Borggrefe M, Haefeli WE, Frey N, Schmidt C. The experimental TASK-1 potassium channel inhibitor A293 can be employed for rhythm control of persistent atrial fibrillation in a translational large animal model. Front Physiol 2021;11:629421.

Wild B, Wurmbach VS, Böhlen F, Kusch MK, Seidling HM, Reich P, Hartmann M, Haefeli WE, Friederich HC, Slaets J. Assessing the perspective of well-being of older patients with multiple morbidities by using the LAVA tool - a person-centered approach. BMC Geriatr 2021;21:427.

Wirbka L, ARMIN study group, Haefeli WE, Meid AD. Estimated thresholds of minimum necessary adherence for effective treatment with direct oral anticoagulants - a retrospective cohort study in health insurance claims data. Patient Prefer Adher 2021;15:2209-2220.

Wurmbach VS, Schmidt SJ, Lampert A, Bernard S, Faller CK, Thürmann PA, Haefeli WE, Seidling HM. Development and pilot-testing of key questions to identify patients' difficulties in medication administration. Patient Prefer Adher 2021;15:2479-2488.

Zülke AE, Luppa M, Röhr S, Weißenborn M, Bauer A, Samos FAZ, Kühne F, Zöllinger F, Döhring J, Brettschneider C, Oey A, Czock D, Frese T, Gensichen J, Haefeli WE, Hoffmann W, Kaduszkiewicz H, König HH ,Thyrian JR, Wiese B, Riedel-Heller SG. Association of mental demands in the workplace with cognitive function in older adults at increased risk for dementia. BMC Geriatr 2021;21:688.

Book chapters

Czock D. Pharmacotherapy in renal failure. In: Schwenger V (ed.). Clinician's guide to nephrology. Munich: Elsevier; 2021;625-636.

Seidling H, Haefeli WE. Drug therapy in elderly patients. In: Schäfer P. General pharmacy. 2nd edition; Stuttgart; Wissenschaftliche Verlagsgesellschaft Stuttgart; 2021: 425-436.